Sunesis plots $15.5M offering to support trial

Sunesis Pharmaceuticals is offering 44.1 million units, each consisting of one share of its common stock and a warrant to purchase 0.5 of a share of its common stock, at a public offering price of $0.35 per unit. The company anticipates it will raise $15.5 million from the offiering, which is expected to close on October 6. The company plans to use the funding to support a Phase III clinical trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia, and for working capital and general corporate purposes.

- here's Sunesis' release on the offering

ALSO: Nasdaq has granted Sunesis a six-month extension for regaining compliance with the market's $1 per share minimum price rule. Report

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.